Update: Where Things Stand on the 340B Rebate Pilot

10 Feb Update: Where Things Stand on the 340B Rebate Pilot

We want to share a brief update on developments since our last communication regarding the federal court’s decision to halt HRSA’s 340B rebate pilot.

The pause remains in effect.
Following the December 29 court order blocking the rebate pilot from taking effect, HRSA formally paused implementation on December 31. Covered entities should continue to receive 340B drugs at the upfront ceiling price, and rebate-based workflows should not begin at this time.

HHS appealed, but the injunction is still in place.
The Department of Health and Human Services appealed the Maine court’s order and requested permission to move forward with the rebate pilot while the appeal is pending. The federal appeals court denied that request, meaning the rebate pilot remains on hold nationwide. The court has set an expedited briefing schedule and could issue a ruling at any time.

Provider groups are actively urging the court to keep the pause in place.
Hospital, academic medical center, and pharmacy associations, including 340B Health, America’s Essential Hospitals, and the AAMC, have filed briefs asking the appeals court to maintain the injunction. Their filings argue that the rebate pilot was rushed, lacked sufficient administrative process, and would create significant financial and operational burdens for covered entities.

HHS and manufacturers continue to push for movement.
At the same time, HHS and several manufacturers have argued publicly that the rebate pilot is necessary to address duplicate discount concerns tied to Medicare drug price negotiations. Manufacturers have emphasized the need for clarity and are pressing the courts to move quickly.

This case is about process, not authority.
The court has not ruled on whether a rebate model is permissible under the 340B statute. Instead, the focus is on whether HRSA followed required administrative law steps before attempting a nationwide rollout. This distinction matters, as it leaves open the possibility of a revised, delayed, or restructured pilot in the future.

What this means for covered entities right now

• The rebate pilot remains paused and will not proceed unless a court lifts the injunction
• Upfront 340B pricing remains in place
• Beacon rebate submissions should not begin
• No immediate operational changes are required

Our recommendation
Pause execution, not preparation. While there is no need to operationalize rebate workflows at this time, this remains an active legal matter with pressure on all sides.

Covered entities should stay informed, preserve planning work already completed, and be prepared for further developments.

We are closely monitoring the appeals process and related litigation and will continue to share updates as the situation evolves.

As the year turns, we know there has been no shortage of change in the 340B world. Wishing you and your teams a steady start to the new year.